key: cord-0746693-hpyfrynl
authors: Minisola, S.; Cipriani, C.; Vigna, E.; Sonato, C.; Colangelo, L.; Monti, F.; Pepe, J.
title: COVID pandemic and denosumab adherence
date: 2022-01-23
journal: Osteoporos Int
DOI: 10.1007/s00198-021-06274-x
sha: c61a0f23ae4e44bdfa0d740484c3fe8d98f3b4d2
doc_id: 746693
cord_uid: hpyfrynl

nan

The coronavirus (COVID 19) pandemic has brought unprecedented disruptions to the provision of health care in every country of the world. Therefore, a number of measures have been implemented with the aim of containing the spread of the virus, the most dramatic being national lockdowns.

These measures challenged many national health systems, sometimes at the expense of patients with both acute and chronic diseases. For example, in order to counteract difficulties with osteoporosis, the American Society for Bone and Mineral Research provided clinical recommendations based on available evidence [1] . For denosumab, one of the most prescribed antiresorptive agents, the panel of experts "strongly recommend the temporary transition to an oral bisphosphonate for patients in whom continued treatment with denosumab is not feasible within 6 months of their most recent prior denosumab injection". Another paper recommended home administration of denosumab, but this may not be possible in all settings [2] .

To the best of our knowledge, there are no reports that have explored the impact of COVID 19 in a real world setting concerning continuation of denosumab treatment and adherence to the ASBMR recommendations. This is of utmost importance because of the well-known deleterious effects that may occur within the first several months following discontinuation. Many studies have shown that following denosumab discontinuation there is accelerated bone turnover, rapid loss of bone mineral density and increased rate of multiple vertebral fracture [3, 4] . Most importantly, a short off-treatment period of 2 to 10 months is enough to produce such catastrophic events [5] . This contrasts with the relatively long-term effect following bisphosphonate withdrawal [6] .

Here we report the experience of our referral centre concerning patient behaviour with denosumab adherence, before and during the pandemic period. Table 1 reports our case series of 20 patients with vertebral fractures following denosumab discontinuation. Main demographic parameters, length of denosumab therapy, date of discontinuation, months elapsed between occurrence of vertebral fracture and denosumab discontinuation and ambulatory presentation are reported. For Italy, March 9, 2020, marked the beginning of the Italian national lockdown that completely limited, until May 4, free circulation. After that, these measures were in part eased, even though some limitations were still in place until June 14, at least in the Lazio region. Restrictive measures were re-imposed in the following periods depending on the number of infected persons, until June 2021.

It can be seen that the number of patients that came to our attention reporting vertebral fractures after denosumab discontinuation dramatically increased during the current year. Indeed, until 2019, we had observed only 8 cases in 7 years; in 2021 (and 2020), we observed 12 cases. According to these last 12 patients, this was mainly due to the inability of adhering to denosumab treatment for a number of reasons, the most important being the inability to access medical facilities during the pandemic period. This was due to mobility restrictions and fear of access to our hospital, selected for the management of COVID patients. We therefore believe that this should be listed among the side effects of the pandemic.

Finally, it is important to note that only patients with symptomatic vertebral fractures came to our attention. It is highly possible that the impact on fracture incidence due the pandemic is even greater than what we observed.

Our letter calls attention to the need to emphasize optimal adherence to denosumab therapy and sharing information about discontinuation directly with patients.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 

Osteoporosis management in the era of COVID-19

Osteoporosis care amidst the prolonged pandemic

Observations following discontinuation of long-term denosumab therapy

Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS

Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Acknowledgements We wish to thank Prof. R. Adler for suggestions and critical review of this letter.Data availability Upon reasonable request, the data can be shared.

Conflicts of interest SM served as speaker for Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, Sandoz, Takeda and Kyowa Kirin. He also served in advisory board of Abiogen, Kyowa Kirin, Pfizer and UCB. Other authors declare no competing interests.